Mycoplasma genitalium 23S rRNA mutations confers resistance to fluoroquinolone and macrolide antibiotics

Accession ARO:3004616
DefinitionMycoplasma genitalium strain M6320 contains mutations that lead to resistance to fluoroquinolone and macrolide antibiotics.
AMR Gene Family23S rRNA with mutation conferring resistance to macrolide antibiotics
Drug Classmacrolide antibiotic, fluoroquinolone antibiotic
Resistance Mechanismantibiotic target alteration
Classification11 ontology terms | Show
Parent Term(s)3 ontology terms | Show
+ confers_resistance_to_drug_class macrolide antibiotic [Drug Class]
+ confers_resistance_to_drug_class fluoroquinolone antibiotic [Drug Class]
+ 23S rRNA with mutation conferring resistance to macrolide antibiotics [AMR Gene Family]
Publications

Tagg KA, et al. 2013. J. Clin. Microbiol. 51(7):2245-9 Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. (PMID 23658265)

Twin J, et al. 2012. PLoS ONE 7(4):e35593 Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. (PMID 22532861)

Jensen JS, et al. 2008. Clin. Infect. Dis. 47(12):1546-53 Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. (PMID 18990060)

Resistomes

Prevalence of Mycoplasma genitalium 23S rRNA mutations confers resistance to fluoroquinolone and macrolide antibiotics among the sequenced genomes, plasmids, and whole-genome shotgun assemblies available at NCBI for 82 important pathogens (see methodological details and complete list of analyzed pathogens). Values reflect percentage of genomes, plasmids, or whole-genome shotgun assemblies that have at least one hit to the AMR detection model. Default view includes percentages calculated based on Perfect plus Strict RGI hits. Select the checkbox to view percentages based on only Perfect matches to AMR reference sequences curated in CARD (note: this excludes resistance via mutation as references in protein variant models are often wild-type, sensitive sequences).

Prevalence: rRNA gene variant model

SpeciesNCBI ChromosomeNCBI PlasmidNCBI WGS
No prevalence data


Detection Models

Model Type: rRNA gene variant model

Model Definition: The rRNA gene variant model is an AMR detection model used to identify ribosomal RNA (rRNA) genes with mutations shown clinically to confer resistance to known antibiotic(s) relative to the wild-type rRNA sequence. Like the protein variant model, rRNA gene variant models detect the presence of an rRNA sequence based on its homolog, and then secondarily search submitted query sequences for a curated mutation. This model includes an rRNA gene reference sequence, a BLASTN bitscore cutoff, and a set of mapped resistance variants. A submitted sequence must have both high homolog to the reference sequence and include a known resistance variant to be detected.

Legend:

  • discovered in clinical, agricultural, or environmental isolates
  • discovered via laboratory selection experiments


Bit-score Cut-off (blastN): 4500

PMID: 22532861A2071T
PMID: 18990060A2071C A2071G A2072G


>gb|L43967.2|+|171728-174461|Mycoplasma genitalium 23S rRNA mutations confers resistance to fluoroquinolone and macrolide antibiotics [Mycoplasma genitalium G37]
ACAATAAGTTACTAAGGGCTTATGGTGGATGCCTTGGCACTAAAAGGCGATGAAGGACGTGTTAACCTGCGATAAGCTTCGGGGAGGTGG
TAAAAACCTGAGATCCGGAGGTGTCCGAATGGAGCAATCTGGTAGCTTGCAAAAGTTACCATTAATTAATGAATTCATAGTTAATTAAAG
CGATACGTGGTGAAGTGAAACATCTCAGTAACCACAGGAAAAGAAAACGAATGTGATTCCGTGTGTAGTGGCGAGCGAAAGCGGAACAGG
CCAAACCTATCTGAGGATAGGGGTTGTAGGGCTTGCATTATGGAAGTTAAAAGGATAGAAGAAGCTGTTGGAAAGCAGCGCCAAAGAGGG
TGATAGCCCCGTATTTGAAATCTTTTTAATACCTAGCAAGAAACCTGAGTAGCTCGAAAAACGTTATTTTGAGTGAATCTGCCCAGACCA
TTGGGTAAGCCTAAATACTAATTAGTGACCGATAGCGAAACAGTACCGTGAGGGAAAGGTGAAAAGAACCCAGAGATGGGAGTGAAATAG
ATTCTGAAACCATATGCCTACAACGTGTCAGAGCACATTAATGTGTGATGGCGTGCGTTTTGAAGTATGAGCCGGCGAGTTATGATAGCA
AGCGTTAGTTAACCAGGAGATGGGGAGCTGTAGCGAAAGCGAGTTTTAAGAGAGCGTTTGTTTGTTATCATAGACCCGAAACGGGTTGAG
CTAGTCATGAGCAGGTTGAAGGTTGAGTAACATTAACTGGAGGACCGAACCGACTCTCGTTGAAACGATAGCGGATGACTTGTGATTAGG
GGTGAAATTCCAATCGAAATCCGTGATAGCTGGTTCTCGTCGAAATAGCTTTAAGGCTAGCGTAAGATCACAAATAAGTGGAGGTAAAGC
TACTGAATGTATGATGGCGCCACCTAGGCGTACTGAATACAATTAAACTCTGAATGCCATTTATTTTATTCTTGCAGTCAGACAGTGGGG
GATAAGCTTCATTGTCAAGAGGGGAAGAGCCCAGATCATTAAATAAGGTCCCCAAAATATACTAAGTGGAAAAGGATGTGAAAGTGCTAA
AACAGCAAGGATGTTGGCTTAGAAGCAGCCATCGTTTAAAGAGTGCGTAACAGCTCACTTGTCGAGTGTTTTTGCGCCGAAGATGTAACG
GGGCTAAGTATATTACCGAATTTATGGATAAGATATTTTTATCTTGTGGTAGACGAGCGTTGTATTGGAGTTGAAGTCAAAGCGTGAGCA
TTGGTGGATCCAATACAAGTGAGAATGCCGGCGTGAGTAACGCTTGGGAGTGAGAATCTCCCAAACCGATTGACTAAGGTTTCCTGGACC
AGGGTCGTCCTTCCAGGGTTAGTCTGGACCTAAGCTGAGGCTGAAGAGCGTAGGCGATGGACAACAGGTTAATATTCCTGTACTTACAGT
TAGACTGATGGAGTGACAAAGAAGGTTATCCACCCCCATTATTGGATTTGGGGATAAACCATAAGGTGGTACAATAGGCAAATCCGTTGT
GCATAACACTGAGTGGTGATGTCGAGTGAACGAGTGATCAAGTAGCGAAGGTGGCAATTAATCATGCTTTCAAGAAAAGCTGCTAGGGCT
AATTTAACTGTAACCAGTACCGAGAACGAACACACGTAGTCAAGGAGAGGATCCTAAGGTTAGCGAGTGAACTATAGCCAAGGAACTCTG
CAAATTAACCCCGTAAGTTAGCGAGAAGGGGTGCTTATCTAAAAGTAAGCCGCAGTGAAGAACGAGGGGGGACTGTTTAACTAAAACACA
ACTCTATGCCAAACCGTAAGGTGATGTATATGGGGTGACACCTGCCCAGTGCTGGAAGGTTAAAGAAGGAGGTTAGCAATTTATTGCAAA
GCTTTTAACTGAAGCCCCAGTGAACGGCGGCCGTAACTATAACGGTCCTAAGGTAGCGAAATTCCTAGTCGGGTAAATTCCGTCCCGCTT
GAATGGTGTAACCATCTCTTGACTGTCTCGGCTATAGACTCGGTGAAATCCAGGTACGGGTGAAGACACCCGTTAGGCGCAACGGGACGG
AAAGACCCCGTGAAGCTTTACTGTAGCTTAATATTGATCAAAACACCACCATGTAGAGAATAGGTAGGAGCAATTGATGCAAGTTCGCAA
GGATTTGTTGATGTGAAATGTGGAATACTACCCTTGGTTATGTTTTGTTCTAATTGGTAACTGTGATCCAGTTTCAAGACAGTGTTAGGT
GGGCAGTTTGACTGGGGCGGTCGCCTCCTAAAAGGTAACGGAGGCGCACAAAGGTACCTTCAGTACGGTTGGAAATCGTATTTAGAGTGT
AATGGTATAAGGGTGCTTGACTGTGAGACTTACAGGTCGAACAGGTGAGAAATCAGGTCATAGTGATCCGGTGGTTCAGTATGGAATGGC
CATCGCTCAACGGATAAAAGCTACTCCGGGGATAACAGGCTGATACTGCCCAAGAGTTCATATCGACGGCAGTGTTTGGCACCTCGATGT
CGACTCATCTCATCCTCGAGCTGAAGCAGGTTCGAAGGGTTCGGCTGTTCGCCGATTAAAGAGATACGTGAGTTGGGTTCAAACCGTCGT
GAGACAGGTTGGTCCCTATCTATTGTGCCCACAGGAAGATTGAAGAGCTTTGCTTCTAGTACGAGAGGACCGGAGCGAGGACACCGCTTA
TGCTCCAGTTGTAGCGCCAGCTGCACCGCTGGGT